The case for & against
Bull & Bear analysis
Mirion Technologies Inc. (NYSE: MIR) is a prominent provider of radiation detection and measurement solutions, primarily targeting the nuclear power, medical, and defense sectors. The company is strategically positioned to leverage increasing global demand for safe and efficient energy, particularly through nuclear power, which is experiencing a resurgence amid capacity shortages and regulatory shifts towards cleaner energy sources. With a focus on technological innovation and strategic acquisitions, such as Paragon and Certrek, Mirion aims to enhance its market presence and capitalize on robust trends within the energy sector and healthcare diagnostics.
Bull says
- ↑Q1 orders rose 42% YoY to $288M; management guides 15–20% Q2 growth
- ↑Q1 revenue increased 28% YoY to $258M, driven by nuclear and medical segments
- ↑Backlog stands at $1.1B (+38% YoY), underpinning multi-quarter revenue visibility
- ↑Executed $16M of $100M share repurchase; strong free cash flow supports returns
- ↑High growth factors and favorable interest-rate sensitivity signal durable expansion
- ↑Macro tailwinds from rising global nuclear adoption and regulatory support
Bear says
- ↓Negative profitability factors indicate weak returns and poor earnings yield
- ↓Q1 EBITDA margins contracted due to margin-dilutive acquisitions
- ↓Reliance on government contracts and nuclear projects heightens regulatory risk
- ↓Beta of 1.72 implies share price vulnerability to market swings
- ↓Emerging SMRs and alternative energy pose competitive threats
- ↓Weak analyst sentiment and potential revision risks could pressure valuation
Investment themes with MIR
Value-oriented stocks outside domestic markets
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- We're off to a strong start in 2026 with significant first quarter order generation. Orders are a bellwether for our business, and they increased 19% in the first quarter to $241 million, excluding M&A-related growth. If we include M&A growth from Paragon and Certrek, orders increased 42% to $288 million. Order volume was notably diverse. Both segments saw meaningful growth, including our RTQA medical business, which faced headwinds in 2025. This is translating into noticeable backlog expansion. Backlog now totals $1.1 billion, up 19% excluding M&A, or 38% including M&A.
- Given the nature of their solution set, they're truly the tip of the spear when it comes to momentum from the nuclear power installed base. The existing nuclear fleet is approaching middle age, and reinvestment is critical to maintain and increase capacity through power upgrades. We'll spend time this morning detailing progress on our large opportunity order pipeline, but let me tease the discussion by noting we secured $50 million of these large opportunity orders in Q1. Moreover, we won an additional $35 million in SMR-related orders in April.
- In nuclear medicine, we remain on track for double-digit organic revenue growth in 2026. This will be our second consecutive year of double-digit organic nuclear medicine growth.
Bear points
- As foreshadowed back in February, margins contracted in the quarter reflecting margin dilutive M&A, one-timers in Q1 of the prior year, and a mixed shift in the legacy nuclear and safety segment, mainly related to our sensing business.
- as foreshadowed on our February earnings call, adjusted EBITDA margins contracted.
- 2%